Dosing commenced in the ATL1102 toxicology studyIn March 2023 the Company announced the start of the nine-month chronic monkey toxicology study of ATL1102 for treatment of Duchenne muscular dystrophy (DMD). Dosing of all animals will be completed by November 2023 with study outcomes expected to be reported in the first half of 2024. Successful completion of the toxicology study is necessary for the FDA to allow dosing of ATL1102 for a term longer than six months in the US, and could lead to expedited program status, including Fast Track or Breakthrough Therapy designation.
ANP has already been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA for the treatment of DMD, and the completion of the toxicology study could pave the way for discussions on accelerated regulatory pathways to registration. The Company may also be eligible to receive a Pediatric Review Voucher (PRV), subject to meeting the eligibility criteria, which could have significant financial value.
The reporting of key study findings from the toxicology study in 1H’24 is expected to coincide with the results from the blinded phase of the ATL1102 Phase IIb DMD clinical study. If the results of both studies are compelling, ANP could share the data package with regulatory bodies for potential discussions on accelerated regulatory pathways to registration.
- Forums
- ASX - By Stock
- anp chart
Dosing commenced in the ATL1102 toxicology studyIn March 2023...
-
- There are more pages in this discussion • 234 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M |
Open | High | Low | Value | Volume |
10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 38503 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 194063 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.099 |
2 | 108491 | 0.098 |
1 | 30927 | 0.097 |
1 | 10004 | 0.096 |
3 | 162157 | 0.095 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 194063 | 5 |
0.110 | 254663 | 3 |
0.115 | 1334300 | 6 |
0.120 | 381142 | 9 |
0.125 | 110429 | 2 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
PER (ASX) Chart |